Akeso Announces Completion of First Dosing in Phase III Clinical Trial of Ivonescimab (PD-1/VEGF) Combination Therapy for Immunotherapy-Resistant NSCLC
Ivonescimab is the only bispecific immunotherapy antibody currently undergoing Phase III registration trials for IO-resistant lung cancer.
In recent years, immunotherapy has achieved significant progress in the treatment of NSCLC. PD-1/L1 inhibitors, whether used as monotherapy or in combination with platinum-based chemotherapy, have become the standard first-line treatment for advanced NSCLC in patients without driver mutations. However, despite these advances, 60%-70% of patients experience disease progression within the first year of treatment.
Currently, there are no approved standard treatment options for IO-resistant NSCLC. Docetaxel is recommended in both China's and international treatment guidelines for immunotherapy-resistant (IO-resistant) NSCLC. However, docetaxel's monotherapy efficacy in the IO-resistant NSCLC patients remains limited. Several Phase III clinical trials investigating IO-resistant lung cancer, including immunotherapy combination therapies studies and ADC therapy studies, have failed to demonstrate positive results.
Mechanistic studies suggest that PD-1 therapy can restore the immune system's anti-tumor activity, while anti-VEGF therapy alleviates VEGF-mediated immune suppression and promotes T-cell infiltration. When combined, these two therapies may produce synergistic effects. Ivonescimab simultaneously targets both PD-1 and VEGF pathways, reversing the immune-suppressive tumor microenvironment and reactivating anti-tumor immune responses. These synergistic mechanisms provide a scientific rationale for using ivonescimab to treat IO-resistant tumors. Furthermore, the positive efficacy and safety data demonstrated in a Phase II study in this indication underscore the significant therapeutic potential of ivonescimab in this difficult to treat patient population.
The ivonescimab regimen has demonstrated remarkable efficacy and excellent safety across multiple tumor types. The ongoing AK112-305/HARMONi-8A Phase III study targeting IO-resistant NSCLC is expected to offer a novel and highly effective treatment option for patients with IO-resistant NSCLC, in line Akesos ' 'Immuno-2.0' strategy.
As the world's leading PD-1/VEGF bispecific antibody, ivonescimab has achieved extensive population coverage for core indications in NSCLC and is positioned across multiple lines of treatment, with the potential to reshape the overall treatment landscape for advanced NSCLC.
Forward-Looking Statement of Akeso, Inc.This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.
About AkesoAkeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available, and 2 new drugs with 2 new indications are under regulatory review for approval. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.
For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.
View original content:https://www.prnewswire.com/news-releases/akeso-announces-completion-of-first-dosing-in-phase-iii-clinical-trial-of-ivonescimab-pd-1vegf-combination--therapy-for-immunotherapy-resistant-nsclc-302518092.html
SOURCE Akeso, Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Topical Drug Delivery Market US$409.0 Billion Forecast by 2030 with 8.8% CAGR
DELRAY BEACH, Fla., Aug 5, 2025 /PRNewswire/ -- The global Topical Drug Delivery Market, valued at US$247.3 billion in 2024 stood at US$268.4 billion in 2025 and is projected to advance at a resilient CAGR of 8.8% from 2025 to 2030, culminating in a forecasted valuation of US$409.0 billion by the end of the period. The growth of the topical drug delivery market can be primarily attributed to factors such as the high prevalence of skin infections, increasing investments in pharmaceutical R&D, the growing emphasis on patient convenience, the high incidence of burn injuries, and the increasing prevalence of chronic diseases. The opportunities for market growth include the growing preference for self-administration, particularly for chronic skin conditions and pain management. Products like transdermal patches, medicated creams, and gels enable patients to manage treatment conveniently at home, reducing their dependence on clinical visits. Download PDF Brochure: Browse in-depth TOC on "Topical Drug Delivery Market" 468 - Tables71 - Figures435 - Pages By product, the topical drug delivery market is segmented into semi-solid formulations, liquid formulations, solid formulations, transdermal products, and other products. Other products include stick, aerosol (spray), and foam. The large share of the semi-solid formulations segment is attributed to its convenience and ease of application, limited side effects that improve patient adherence, and the ability to topically deliver a wide variety of drug molecules compared to other formulations. By application, the market is segmented into dermal drug delivery, ophthalmic drug delivery, rectal drug delivery, vaginal drug delivery, and nasal drug delivery. In 2024, the dermal drug delivery segment accounted for the largest share of the market. The large share of this segment is attributed to the several key advantages offered, such as the ease of use and increased patient compliance for long-term treatment in conditions for chronic pain or skin disorders. Dermal drugs also have fewer regulatory requirements than ophthalmic products, which leads to increasingly accessible product launches and broad adoption. By end user, the market is segmented into home care settings, ambulatory surgery centers, hospitals & clinics, burn care centres, and other end users. The home care settings segment accounted for the largest share of the market in 2024. Topical drug delivery systems are increasingly gaining prominence, not just as an alternative route of drug delivery but also as point-of-care devices in home care settings. The market's growth is primarily attributed to improved patient accessibility owing to high awareness and comfort. By geography, in 2024, North America accounted for the largest share of the topical drug delivery market, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Market growth in this region is characterized by the availability of favorable reimbursement options, increasing awareness about novel pharmaceutical drug delivery technologies, the implementation of favorable government initiatives, growing affordability and per capita healthcare expenditure, and the presence of several global pharmaceutical giants. Request Sample Pages : The prominent players in the topical drug delivery market are Johnson & Johnson Services, Inc. (US), Galderma (Switzerland), Bayer AG (Germany), Novartis AG (Switzerland), AbbVie Inc. (US), GSK Plc. (UK), Bausch Health Companies Inc. (Canada), Glenmark Pharmaceuticals Limited (India), Hisamitsu Pharmaceuticals Inc. (Japan), Cipla (India), Boehringer Ingelheim International GmbH (Germany), Pfizer Inc. (US), Teva Pharmaceuticals Industries Ltd. (Israel), Viatris Inc. (US), Organon group of companies (US), , Solventum (US), Crescita Therpeautics Inc. (Canada), Luye Pharma Group (China), Lead Chemical Co., Ltd. (Japan), Purdue Pharma L.P. (US), Lavipharm (Greece), CMP Pharma, Inc. (Germany), Encore Dermatology, Inc. (US), Rusan Pharma Ltd. (India) and AdhexPharma (France). Johnson & Johnson Private Limited (US): The company primarily focuses on human health and well-being. J&J operates through two business segments: Innovative Medicine and MedTech. Topical drug delivery products fall under the Innovative Medicine segment, which is focused on six therapeutic areas: Immunology (e.g., rheumatoid arthritis, inflammatory bowel disease, and psoriasis), Infectious Diseases (e.g., HIV/AIDS), Neuroscience (e.g., mood disorders, neurodegenerative disorders, and schizophrenia), Oncology (e.g., prostate cancer and hematologic malignancies), Cardiovascular and Metabolism (e.g., thrombosis and diabetes), and Pulmonary Hypertension (e.g., Pulmonary Arterial Hypertension). The company has a strong presence across North America, Europe, the Asia Pacific, and Africa. Galderma (Switzerland) Galderma offers premium brands and services across injectable aesthetics, dermatological skincare, and therapeutic dermatology. The company provides topical products under all three segments. Injectable Aesthetics consists of hyaluronic acid (HA) fillers and botulinum neuromodulators. Dermatological skincare consists of consumer care brands such as Cetaphil, with its wide range of skincare products for all ages; Benzac and Differin OTC for mild-to-moderate acne; and Loceryl, used to treat fungal nail infections. The company operates globally with research and development centers and manufacturing sites throughout the Asia Pacific, Europe, the Middle East, Africa, and North & Latin America. For more information, Inquire Now! Related Reports: Drug Discovery Services Market Injectable Drug Delivery Market Pharmaceutical Drug Delivery Market Artificial Intelligence in Drug Discovery Market Pharmaceutical Contract Manufacturing Market Get access to the latest updates on Topical Drug Delivery Companies and Topical Drug Delivery Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
4 hours ago
- Business Wire
SCH Capital Holdings, Inc. Adds Health Care Compensation Management Technology Capability to Portfolio
CHICAGO--(BUSINESS WIRE)--SCH Capital Holdings, Inc., the nation's leading human capital information management holding company for health care and not-for-profit/tax-exempt organizations, has acquired Boston-based Statera. "When we combine Statera's focus on academic medical centers alongside Clinician Nexus's integrated delivery systems expertise, we are able to serve the entire health care marketplace with specialized compensation management expertise in both segments." Formed in 2020, Statera is a group of human-focused compensation experts and health care technologists who provide timely and actionable compensation and care insights to hospitals, medical groups, and clinicians. Statera's platform offers a comprehensive suite of tools that optimize clinical team performance and automate compensation administration. Statera will continue to enable health systems to automate physician compensation through its technology platform as part of Clinician Nexus, a SCH Capital Holdings, Inc. technology company. Together, these combined capabilities will provide health care organizations with a broad mix of technology tools that empower health systems and medical groups to align compensation, productivity, and incentives for their physicians and APPs. 'When we combine Statera's focus on academic medical centers alongside Clinician Nexus's integrated delivery systems expertise, we are able to serve the entire health care marketplace with specialized compensation management expertise in both segments,' said Ted Chien, President and CEO of SCH Capital Holdings, Inc. 'We are excited to join the SCH Capital Holdings, Inc., family and integrate our expertise into the Clinician Nexus brand,' said Amy Jackson, CEO of Statera. 'The company's gold standard reputation and Clinician Nexus's established platform will enable us to reach new markets. Together, we'll be able to deliver the next generation of compensation management technology to a broader audience and make a greater impact across the health care ecosystem.' About SCH Capital Holdings, Inc. SCH Capital Holdings, Inc., is the parent company of independent operating brands SullivanCotter, Clinician Nexus, Lotis Blue Consulting and C3 Nonprofit Consulting Group. This collection of complementary brands helps organizations solve complex workforce issues by enabling people, processes and technology aimed at large-scale business transformation. For more information, email info@ or call 888.739.7039.
Business Wire
5 hours ago
- Business Wire
Butterfly Network Advances AI-Powered Aortic Valve and Aorta Screening with New Research and Training Tools
BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced its role in new research demonstrating the potential for machine learning (ML) models to support early detection of aortic stenosis (AS) using handheld ultrasound devices. The study, conducted by Tufts Medical Center and published in European Heart Journal – Imaging Methods and Practice, demonstrates that a ML model fine-tuned for use on Butterfly iQ+ devices can achieve high accuracy in identifying AS. The findings support the value of ML model development, and ultimately, are a positive step toward portable screening for earlier detection of this life-threatening condition. Aortic stenosis, a narrowing of the aortic valve, affects over 13% of Americans over 75 years old and is often missed until it's advanced and symptomatic. Studies(1, 2) suggest that a significant number of AS cases remain undiagnosed, particularly among underserved and aging populations. This delay in diagnosis is associated with higher risk procedures, worse outcomes, and increased healthcare costs. As earlier identification and treatments of AS are increasingly associated with better patient outcomes, the need for upstream, accessible screening is critical. 'This research shows a promising path forward where lower-level providers, not just cardiologists or trained sonographers, could screen for aortic stenosis using AI-assisted handheld ultrasound,' said Dr. John Martin, co-author of the study and Butterfly's Chief Medical Officer Emeritus. 'This opens the door to early detection in a wide variety of care venues including primary care offices, long term care facilities, urgent care facilities and even in the home.' The study validated that an ML model trained on hospital-grade ultrasound images performed well when adapted to Butterfly's handheld ultrasound device. After fine-tuning the final layer of a neural network, researchers achieved an area under the receiver operator characteristic curve (AUROC) of 0.94 for differentiating between no aortic stenosis and any degree of aortic stenosis on handheld ultrasound images – a level of accuracy that supports potential clinical use in screening workflows. In a related development, Butterfly has just released the latest expansion of its Butterfly ScanLab™ AI-powered ultrasound education app: an Aorta Exam Protocol. This educational app harnesses animations, anatomical labeling, and a quality indicator to help teach users how to scan the abdominal aorta and recognize normal anatomy. With that training, users can then use POCUS to detect life-threatening conditions like abdominal aortic aneurysms (AAA) and dissections. Designed for ease of use on an iPad, the module is included in every Butterfly membership and compatible with existing Butterfly probes. Joseph DeVivo, President, CEO, and Chairman of Butterfly Network concluded, 'Early detection saves lives, but access to imaging remains a major barrier. This work is about democratizing diagnostics. With AI and education working hand in hand, we're empowering more providers to deliver proactive care in places that were never possible before.' About Butterfly Network Butterfly Network, Inc. (NYSE: BFLY) is a healthcare company driving a digital revolution in medical imaging with its proprietary Ultrasound-on-Chip™ semiconductor technology and ultrasound software solutions. In 2018, Butterfly launched the world's first handheld, single-probe, whole-body ultrasound system, Butterfly iQ. The iQ+ followed in 2020, and the iQ3 in 2024, each with improved processing power and performance by leveraging Moore's Law. The iQ3 earned Best Medical Technology at the 2024 Prix Galien USA Awards, a prestigious honor and one of the highest accolades in healthcare. Butterfly's innovations have also been recognized by Fierce 50, TIME's Best Inventions and Fast Company's World Changing Ideas, among other achievements. Butterfly combines advanced hardware, intelligent software, AI, services, and education to drive adoption of affordable, accessible imaging. Clinical publications demonstrate that its handheld ultrasound probes paired with Compass™ enterprise workflow software, can help hospital systems improve care workflows, reduce costs, and enhance provider economics. With a cloud-based solution that enables care anywhere through next-generation mobility, Butterfly aims to democratize healthcare by addressing critical global healthcare challenges. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit:
